Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] ISU PETASYS (007660) – New Facility Investment / 2024-11-08

Posted on November 8, 2024August 1, 2026 By K-STOCK Editor No Comments on [Disclosure] ISU PETASYS (007660) – New Facility Investment / 2024-11-08

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

ISU PETASYS has decided on a large-scale new facility investment worth KRW 400.0B (149.9% of total equity) to build new plant capacity and install equipment aimed at boosting sales revenue.

📊 [Key Disclosure Details & Financial Summary]

  1. Investment Type & Target: New Facility Investment (New plant expansion and equipment investment)
  2. Investment Details:
  • Investment Amount: KRW 400.0B (KRW 400,000,000,000)
  • Total Equity: KRW 266,778,163,292
  • Ratio to Total Equity: 149.9%
  1. Investment Purpose: Revenue increase through new factory construction and equipment investment
  2. Investment Period: November 08, 2024 – December 31, 2028
  3. Board Resolution Date: November 08, 2024
  4. Financing Method & Other Notes:
  • Funding will be covered via internal funds and external financing according to future financial plans.
  • Investment amount and period are subject to change during implementation.
  • This disclosure serves as the finalized disclosure regarding the unconfirmed response disclosure filed on September 20, 2024.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Large-scale Facility Investment Execution and Progress of Capital Expenditure

The company decided on a KRW 400.0B facility investment to construct new factory capacity and purchase equipment. Monitoring whether the financing and capital expenditure proceed as planned over the specified investment period is important to confirm the execution status of this investment plan. Relevant details can be tracked through the ‘Management Discussion and Analysis’ section and financial statement footnotes in future periodic filings.

📢 Disclaimer & Source Notice

Source: This content has been newly structured and created based on official filing data from the Financial Supervisory Service DART system.

Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific securities. All investment decisions and financial liabilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] ISU PETASYS (007660) – Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2024-11-08
Next Post: [Disclosure] PSK Holdings (031980) – Investor Relations (IR) Host / 2024-11-08

Related Posts

[Disclosure] Hanwha Systems (272210) – Corrected Filing for Subsidiary Hanwha Systems USA Corporation Capital Increase (Payment Date Revised to Dec 22, 2025) Disclosures
[Disclosure] Hanwha Aerospace (012450) – Trading Suspension Due to Corporate Spin-off Electronic Registration Change/Cancellation (Effective August 29, 2024) Disclosures
[Disclosure] Jusung Engineering (036930) – Consolidated Financial Results (Provisional) / 2025-07-30 Semiconductors
[Disclosure] ALTEOGEN (196170) – Results of Annual General Meeting of Shareholders / 2026-03-31 Disclosures
[Disclosure] Hana Micron (067310) – Corporate Value-Up Plan (Voluntary Disclosure) / 2025-05-14 Semiconductors
[Disclosure] Hanmi Semiconductor (042700) – Single Sales and Supply Contract / 2025-05-16 Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme